Avidity Biosciences, INC Form 4 insider transactions

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, disposed of common stock and stock options following the merger agreement with Novartis AG.

Avidity Biosciences director Tamar Thompson disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger agreement with Novartis AG.

Avidity Biosciences' CFO, Michael F. MacLean, disposed of all common stock and stock options following the company's acquisition by Novartis AG.

Avidity Biosciences Director Simona Skerjanec disposed of all her common stock and stock options as part of the merger agreement with Novartis AG.

Avidity Biosciences' Chief Medical Officer disposed of all common stock and stock options following the company's acquisition by Novartis AG for $72.00 per share.

Avidity Biosciences' President and CEO, Sarah Boyce, disposed of all her common stock and stock options as part of the acquisition by Novartis AG.

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, disposed of common stock and stock options as part of the previously announced merger with Novartis.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, disposed of common stock and stock options as part of the previously announced merger with Novartis.

Avidity Biosciences Director Troy Edward Wilson disposed of all his common stock and stock options as part of the previously announced merger with Novartis at $72.00 per share.

Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, disposed of all her common stock and stock options as part of the merger agreement with Novartis AG.

Avidity Biosciences director Noreen Henig disposed of all common stock and stock options as part of the company's acquisition by Novartis AG for $72.00 per share.

Avidity Biosciences Director Jean Jinsun Kim disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger with Novartis AG.

Avidity Biosciences director Arthur A. Levin disposed of all his common stock and stock options as part of the previously announced merger with Novartis AG.

Avidity Biosciences Director Edward M. Kaye disposed of common stock and stock options as part of the previously announced merger with Novartis AG.

Avidity Biosciences Director Carsten Boess disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger with Novartis AG.

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, disposed of common stock and stock options as part of the previously announced merger with Novartis AG.

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger agreement with Novartis AG.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, reported a non-discretionary sale of common stock totaling 4,895 shares to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' President and CEO, Sarah Boyce, sold 14,387 shares of common stock at $72.45 per share to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, sold shares to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' CFO, Michael F. MacLean, sold 4,542 shares of common stock at $72.45 per share to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences director Arthur A. Levin sold 1,758 shares of common stock in a non-discretionary transaction to cover tax withholding obligations.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, executed a non-discretionary 'sell-to-cover' transaction to satisfy tax withholding obligations related to RSU vesting.

Avidity Biosciences President and CEO, Sarah Boyce, sold 8,576 shares of common stock on January 7, 2026, to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, sold 3,727 shares of common stock at $72.23 per share to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, sold 1,965 shares of common stock at $72.23 per share to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, sold 2,374 shares of common stock at $72.23 per share to cover tax withholding obligations.

Avidity Biosciences' Chief Financial Officer, Michael F. MacLean, sold 1,974 shares of common stock to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, sold 2,373 shares of common stock at $72.23 per share to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, sold 2,373 shares of common stock to cover tax withholding obligations related to RSU vesting.